Cyclosporin: A review of its pharmacology and clinical potential in the treatment of systemic lupus erythematosus

BioDrugs

Volumn 7, Issue 6, 1997, Pages 483-501

  Noble, S ^a   Wagstaff, A J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUOCORTOLONE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; PREDNISONE;

DRUG EFFICACY; DRUG TOLERABILITY; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTOXICITY; PARESTHESIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030743380     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707060-00006     Document Type: Review

References (48)

1. 1. D. Faulds K.L. Goa P. Benfield 1993 Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders Drugs 45 953 1040 7691501 10.2165/00003495-199345060-00007 1:CAS:528:DyaK3sXmtFKlsL0%3D Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993 Jun; 45:953–1040.
2. 2. R.M. Graham 1994 Cyclosporine: mechanisms of action and toxicity Cleve Clin J Med 61 308 13 7923750 1:STN:280:DyaK2M%2FgvVWqtQ%3D%3D Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med 1994 Jul-Aug; 61: 308–13.
3. 3. E.M. Hay M.L. Snaith 1995 Systemic lupus erythematosus and lupuslike syndromes BMJ 310 1257 61 7767201 10.1136/bmj.310.6989.1257 1:STN:280:DyaK2M3osVKrug%3D%3D Hay EM, Snaith ML. Systemic lupus erythematosus and lupuslike syndromes. BMJ 1995 May 13; 310: 1257–61.
4. 4. L. Kater F.H.J. Gmelig-Meyling R.H.W.M. Derksen 1995 Immunopathogenesis and therapy of systemic lupus erythematosus Clin Immunother 471 93 Kater L, Gmelig-Meyling FHJ, Derksen RHWM, et al. Immunopathogenesis and therapy of systemic lupus erythematosus. Clin Immunother 1995 Dec; 4: 471–93.
5. 5. G.B. Appel A. Valeri 1994 The course and treatment of lupus nephri tis Annu Rev Med 45 525 37 8198400 10.1146/annurev.med.45.1.525 1:STN:280:DyaK2c3ls1Oruw%3D%3D Appel GB, Valeri A. The course and treatment of lupus nephri tis. Annu Rev Med 1994; 45: 525–37.
6. 6. Brown M, Schrieber L. Systemic lupus erythematosus. Curr Ther 1996 Aug: 53-8.
7. 7. T.W. Redford R.E. Small 1995 Update on pharmacotherapy of sys temic lupus erythematosus Am J Health System Pharm 52 2686 95 1:STN:280:DyaK287ntVGmsQ%3D%3D Redford TW, Small RE. Update on pharmacotherapy of sys temic lupus erythematosus. Am J Health System Pharm 1995 Dec I; 52: 2686–95.
8. 8. L.E. Adams E.V. Hess 1991 Drug-related lupus: incidence, mecha nisms and clinical implications Drug Saf 6 431 49 1793523 10.2165/00002018-199106060-00004 1:STN:280:DyaK387nt1aruw%3D%3D Adams LE, Hess EV. Drug-related lupus: incidence, mecha nisms and clinical implications. Drug Saf 1991 Nov-Dec; 6: 431–49.
9. 9. J.P. Uetrecht 1996 Drug-induced lupus: possible mechanisms and their implications for prediction of which new drugs may induce lupus Expert Opin Invest Drug 851 60 Uetrecht JP. Drug-induced lupus: possible mechanisms and their implications for prediction of which new drugs may induce lupus. Expert Opin Invest Drug 1996 Jul; 5: 851–60.
10. 10. D.A. Fox W.J. McCune 1994 Immunosuppressive drug therapy of sys temic lupus erythematosus Rheum Dis Clin North Am 265 99 Fox DA, McCune WJ. Immunosuppressive drug therapy of sys temic lupus erythematosus. Rheum Dis Clin North Am 1994 Feb; 20: 265–99.
11. 11. P.A. Miescher A. Miescher 1985 Combined ciclosporin-steroid treat ment of systemic lupus erythematosus R. Schinuler Ciclosporin in autoimmune diseases. Proceedings of the 1st International Symposium, Basle, Switzerland, March 18-20, 1985 Springer-Verlag Berlin, Heidelberg, New York, Tokyo 337 45 Miescher PA, Miescher A. Combined ciclosporin-steroid treat ment of systemic lupus erythematosus. In: Schinuler R, editor. Ciclosporin in autoimmune diseases. Proceedings of the 1st International Symposium, Basle, Switzerland, March 18-20, 1985. Berlin, Heidelberg, New York, Tokyo: Springer-Verlag, 1985:337–45.
12. 12. M. Tokuda N. Kurata A. Mizoguchi 1994 Effect of low-dose cyclosporin A on systemic lupus erythematosus Arthritis Rheum 551 8 Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus. Arthritis Rheum 1994 Apr; 37: 551–8.
13. 13. J. Lukac J. Roovensky L. Rauova 1995 Cyclosporin A in the treatment of systemic connective tissue diseases [abstract] Rheumatol Eur 24 Suppl.3 170 Lukac J, Roovensky J, Rauova L, et al. Cyclosporin A in the treatment of systemic connective tissue diseases [abstract]. Rheumatol Eur 1995; 24 Suppl. 3: 170.
14. 14. P.A. Miescher H. Favre R. Lemoine 1994 Drug combination therapy of systemic lupus erythematosus Springer Semin Immunopathol 16 295 311 7716710 1:STN:280:DyaK2M3jt1Ojtg%3D%3D Miescher PA, Favre H, Lemoine R, et al. Drug combination therapy of systemic lupus erythematosus. Springer Semin Immunopathol 1994; 16: 295–311.
15. 15. D. Caccavo B. Laganà A.P. Mitterhofer 1997 Long-term treat ment of systemic lupus erythematosus with cyclosporin A Arthritis Rheum 40 I 27 35 9008597 10.1002/art.1780400106 1:CAS:528:DyaK2sXotFOqug%3D%3D Caccavo D, Laganà B, Mitterhofer AP, et al. Long-term treat ment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997 Jan; 40 (I): 27–35.
16. 16. G. Feutren S. Querin L.H. Noël 1987 Effects of cyclosporine in severe systemic lupus erythematosus J Pediatr 111 6PtII 1063 8 3681569 1:STN:280:DyaL1c%2FmtF2jsQ%3D%3D Feutren G, Querin S, Noël LH, et al. Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 1987; 111 (6 Pt II): 1063–8.
17. 17. K. Manger J.R. Kalden B. Manger 1996 Cyclosporin A in the treat ment of systemic lupus erythematosus: results of an open clinical study Br J Rheumatol 669 75 Manger K, Kalden JR, Manger B. Cyclosporin A in the treat ment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996 Jul; 35: 669–75.
18. 18. J. Radhakrishnan C.L. Kunis V. D’Agati 1994 Cyclosporine treatment of lupus membranous nephropathy Clin Nephrol 42 147 54 7994932 1:STN:280:DyaK2M%2Foslanug%3D%3D Radhakrishnan J, Kunis CL, D’Agati V, et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994 Sep;42: 147–54.
19. 19. H. Favre P.A. Miescher Y.P. Huang 1989 Ciclosporin in the treat ment of lupus nephritis Am J Nephrol 9 Suppl.1 57 60 2646927 10.1159/000168040 Favre H, Miescher PA, Huang YP, et al. Ciclosporin in the treat ment of lupus nephritis. Am J Nephrol 1989; 9 Suppl. 1: 57–60.
20. 20. A. Fahr 1993 Cyclosporin clinical pharmacokinetics Clin Pharmacokinet 472 95 Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993 Jun; 24: 472–95.
21. 21. S. Noble A. Markham 1995 Cyclosporin: a review of the pharmaco kinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) Drugs 50 5 924 41 8586033 10.2165/00003495-199550050-00009 1:CAS:528:DyaK28Xit12nuw%3D%3D Noble S, Markham A. Cyclosporin: a review of the pharmaco kinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®). Drugs 1995 Nov; 50 (5): 924–41.
22. 22. B.D. Kahan J. Dunn C. Fitts 1995 Reduced inter-and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals Transplantation 59 505 11 7878754 1:STN:280:DyaK2M7osVehsw%3D%3D Kahan BD, Dunn J, Fitts C, et al. Reduced inter-and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995 Feb 27; 59: 505–11.
23. 23. C. Bombardier D.D. Gladman M.B. Urowitz 1992 Derivation of the SLEDAI: a disease activity index for lupus patients Arthritis Rheum 35 6 630 40 1599520 10.1002/art.1780350606 1:STN:280:DyaK383oslWrtg%3D%3D Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992 Jun; 35 (6): 630–40.
24. 24. R. Bambauer B. Reinelt H. Pees 1989 Therapeutic plasma ex change and cyclosporin A in severe systemic lupus erythematosus Transfus Sci 10 2 147 54 10.1016/0955-3886(89)90021-0 Bambauer R, Reinelt B, Pees H, et al. Therapeutic plasma ex change and cyclosporin A in severe systemic lupus erythematosus. Transfus Sci 1989; 10 (2): 147–54.
25. 25. A. Bengtsson C. Ståhl-Halengren O. Nived 1996 Efficacy and safety of low-dose cyclosporin A on nine patients with systemic lupus erythematosus [abstract no. 12] Scand J Rheumatol 106 10 Bengtsson A, Ståhl-Halengren C, Nived O, et al. Efficacy and safety of low-dose cyclosporin A on nine patients with systemic lupus erythematosus [abstract no. 12]. Scand J Rheumatol 1996 Suppl. 106: 10.
26. 26. Chen S-L. Cyclosporin A therapy for SLE [abstract]. 8th AP-LAR Congress of Rheumatology; 1996 Apr 21-26; Melbourne, S17.
27. 27. H. Favre P.A. Miescher R. Lemoine 1992 Combined ciclosporin A/steroid treatment for SLE patients [abstract no. 681] J Autoimmun 5 8 10.1016/0896-8411(92)90070-7 Favre H, Miescher PA, Lemoine R. Combined ciclosporin A/steroid treatment for SLE patients [abstract no. 681]. J Autoimmun 1992; 5 Suppl. A: 8.
28. 28. H. Favre R. Lemoine P.A. Miescher 1992 Systemic lupus erythema tosus [abstract] Kidney Int 42 801 Favre H, Lemoine R, Miescher PA. Systemic lupus erythema tosus [abstract]. Kidney Int 1992; 42: 801.
29. 29. Dammacco F, Rizzi R, Ferraccioli GF, et al. Effect of lowdose cyclosporin A in association with corticosteroids vs corticosteroids alone on SLE disease activity: 12 month results of a randomized pilot study [abstract no. 93). International Symposium on Clinical Immunology; 1995 Jul 20-23; San Francisco.
30. 30. M. Balletta D. Sabella P. Magri 1992 Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis Contrib Nephrol 99 129 30 1458919 1:STN:280:DyaK3s%2Fpt1Ojsg%3D%3D Balletta M, Sabella D, Magri P, et al. Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 1992; 99: 129–30.
31. 31. C. Dostal V. Tesar I. Rychlik 1995 Cyclosporine in lupus nephri tis [abstract] Arthritis Rheum 38 S303 Dostal C, Tesar V, Rychlik I, et al. Cyclosporine in lupus nephri tis [abstract]. Arthritis Rheum 1995 Sep; 38 Suppl.: S303.
32. 32. S. Pons H. Alcocer J.C. Alonso 1993 Cyclosporin A treatment of corticoresistant nephrotic syndrome secondary to lupus nephropathy [abstract] Nephrol Dial Transplant 8 765 Pons S, Alcocer H, Alonso JC, et al. Cyclosporin A treatment of corticoresistant nephrotic syndrome secondary to lupus nephropathy [abstract]. Nephrol Dial Transplant 1993; 8: 765.
33. 33. V. Tesar C. Dostal I. Rychlik 1996 Long-term treatment of lupus nephritis with cyclosporine [abstract] Nephrol Dial Transplant A90 Tesar V, Dostal C, Rychlik I, et al. Long-term treatment of lupus nephritis with cyclosporine [abstract]. Nephrol Dial Transplant 1996 Jun; 11: A90.
34. 34. G. Feutren 1992 The optimal use of cyclosporin A in autoimmune diseases [published erratum appears in J Autoimmun 1992 Aug;5(4):545] J Autoimmun 5 183 95 1503611 10.1016/0896-8411(92)90033-M Feutren G. The optimal use of cyclosporin A in autoimmune diseases [published erratum appears in J Autoimmun 1992 Aug;5(4):545]. J Autoimmun 1992 Apr; 5 Suppl A: 183–95.
35. 35. R. Bambauer G.A. Jutzler H. Pees 1985 Ciclosporin (CyA) and therapeutic plasma exchange in steroid-resistant SLE R. Schindler Ciclosporin in autoimmune diseases. 1st International Symposium, Basle, Switzerland, March 18-20, 1985 Springer-Verlag Berlin, Heidelberg, New York, Tokyo 346 55 Bambauer R, Jutzler GA, Pees H, et al. Ciclosporin (CyA) and therapeutic plasma exchange in steroid-resistant SLE. In: Schindler R, editor. Ciclosporin in autoimmune diseases. 1st International Symposium, Basle, Switzerland, March 18-20, 1985. Berlin, Heidelberg, New York, Tokyo: Springer-Verlag, 1985:346–55.
36. 36. Yin P-D, Yang Y-Y. Clinical evaluation on cyclosporin A in treatment of lupus nephritis (abstract). 8th APLAR Congress of Rheumatology; 1996 Apr 21-26: P105.
37. 37. A. Doria L. Lenardo Di S. Vario 1992 Cyclosporin A in a preg nant patient affected with systemic lupus erythematosus Rheumatol Int 77 8 Doria A, Di Lenardo L, Vario S, et al. Cyclosporin A in a preg nant patient affected with systemic lupus erythematosus. Rheumatol Int 1992 Jun; 12: 77–8.
38. 38. M.M. Hussein J.M.V. Mooij H. Roujouleh 1993 Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy Clin Nephrol 160 3 Hussein MM, Mooij JMV, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993 Sep; 40: 160–3.
39. 39. Nonspecific immunosuppressive therapies still the mainstay for SLE. Drug Ther Perspect 1996 Jul 8; 8 (1): 5-9.
40. 40. D.J. Wallace T. Podell J. Weiner 1981 Systemic lupus erythematosus — survival patterns JAMA 245 9 934 8 7463697 10.1001/jama.1981.03310340024021 1:STN:280:DyaL3M7itVWmtg%3D%3D Wallace DJ, Podell T, Weiner J, et al. Systemic lupus erythematosus — survival patterns. JAMA 1981; 245 (9): 934–8.
41. 41. D.D. Gladman 1995 Prognosis and treatment of systemic lupus erythematosus Curr Opin Rheumatoi 402 8 Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatoi 1995 Sep; 7: 402 8.
42. 42. M. Abu-Shakra M.B. Urowitz D.D. Gladman 1995 Mortality studies in systemic lupus erythematosus. Results from a single centre. II. Predictor variables for mortality J Rheumatoi 22 1265 70 1:STN:280:DyaK28%2Flslarsg%3D%3D Abu-Shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in systemic lupus erythematosus. Results from a single centre. II. Predictor variables for mortality. J Rheumatoi 1995; 22: 1265–70.
43. 43. V. Nayak J.M. Esdaile 1996 The efficacy of antimalarials in systemic lupus erythematosus Lupus 5 1 S23 27 8803906 10.1177/096120339600500106 1:CAS:528:DyaK28XkvFaltLo%3D Nayak V, Esdaile JM. The efficacy of antimalarials in systemic lupus erythematosus. Lupus 1996 Jun; 5 Suppl. 1: S23–27.
44. 44. E.J. Lewis L.G. Hunsicker H.-S. Lan 1992 A controlled trial of plasmapheresis therapy in severe lupus patients N Engl J Med 326 21 1373 9 1569973 10.1056/NEJM199205213262101 1:STN:280:DyaK383js1OjtQ%3D%3D Lewis EJ, Hunsicker LG, Lan H-S, et al. A controlled trial of plasmapheresis therapy in severe lupus patients. N Engl J Med 1992 May 21; 326 (21): 1373–9.
45. 45. P.J.W. Venables 1993 Diagnosis and treatment of systemic lupus ery thematosus BMJ 307 663 6 8401055 10.1136/bmj.307.6905.663 1:STN:280:DyaK2c%2FgsVartQ%3D%3D Venables PJW. Diagnosis and treatment of systemic lupus ery thematosus. BMJ 1993 Sep 11; 307: 663–6.
46. 46. V.C. Ho D.M. Zloty 1993 Lmmunosuppressive agents in dermatology Dermatol Clin 73 85 Ho VC, Zloty DM. Lmmunosuppressive agents in dermatology. Dermatol Clin 1993 Jan; 11: 73–85.
47. 47. W.J. McCune 1996 Lmmunosuppressive drug therapy Curr Opin Rheumatoi 183 7 McCune WJ. Lmmunosuppressive drug therapy. Curr Opin Rheumatoi 1996 May; 8: 183–7.
48. 48. G. Deray M. Benhmida P. Le-Hoang 1992 Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis Ann Intern Med 117 578 83 1524331 1:STN:280:DyaK38zpvVajtw%3D%3D Deray G, Benhmida M, Le-Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992 Oct 1; 117: 578–83.